Akers Biosciences Share Discussion Threads

[mcmather] 19/10/2015 08:52

Here's a more recent piece on that heart attack test:

The new £5 blood test that warns of heart attack and could reduce number of patients being admitted to hospital by two-thirds

[norbus] 16/10/2015 08:05

Spivvy desperation no less; I think its over bar the shouting and what Raymond manages to take off the table; I say that with confidence with benefit of what mcm posted about developing a test that Scots beat them 2 2 years later

[mcmather] 09/10/2015 20:28

Looks that way though I bet that the scots do not have, ahem, the "new bluetooth-enabled reading device, BreathScan Lync(TM) and associated BreathScan(TM) mobile app"......

Anyhow, is Dr Raymond Akers jnr a clown? Have the books been represented beyond any doubt whatsoever re what was paid or not paid (actual physical money and stock provided in return) re the "Distribution Agreement for Infectious Disease and Cholesterol Rapid Tests in Middle East, Australia, Singapore....with Thirty Six Strategies General Trading LLC ("36S"), for the sale of the Company's PIFA PLUSS Infectious Disease Rapid Assay product line and Tri-Cholesterol"? RNS 7 May 2014 refers in addition to subsequent published results:


The evidence heard at this hearing could be interesting:

AKERS BIOSCIENCES INC. v. THIRTY SIX STRATEGIES GENERAL TRADING L.L.C. et al

Plaintiff: AKERS BIOSCIENCES INC.

Defendant: THIRTY SIX STRATEGIES GENERAL TRADING L.L.C., FRANK RUNGE and GAVIN MORAN; ex board member no less....

Case Number:1:2015cv07316
Filed: October 6, 2015

[norbus] 08/10/2015 16:57

so? is the test RNS'd by Akers ? Jackpot missed again? Sadly The Scots beat him to it

[mcmather] 08/10/2015 15:16

Commenting just based upon his results since Akers came to market in 2002, he is clearly a massive bell.

The below formed part of the rns from 28 July 2014:
Currently available tests for cardiac muscle tissue damage require a blood draw and the use of an interpretation device (a reader); and typically take 20-30 minutes to complete in a laboratory. Konica Minolta, at its own cost, has asked Akers to study a test which can be performed in under 10 minutes, using only a small blood sample obtained from a finger stick; and which can be read visually at the point of care. "Konica Minolta has asked Akers to study a diagnostic test which, if successful, would be the world's first test to diagnose a heart attack in real-time," added Dr. Akers.


This is from today's BBC website:
A blood test can more than halve the number of people admitted to hospital with a suspected heart attack, say doctors.

They say the rapid test, which looks for a chemical in the blood, would reduce stress for patients, save money and ease pressure on hospital wards.

Trials on 6,304 people, published in the Lancet medical journal, suggested it was 99.6% accurate.

The British Heart Foundation said the test would produce faster answers without affecting patient safety

[norbus] 08/10/2015 09:57

Like it or not they will walk the share price up to a level ( 250/300 )that would allow another funding round

[norbus] 07/10/2015 06:30

A wise poem. send it with a hand mirror to the Akerman you admire

[mcmather] 06/10/2015 22:44

Still here; just very little time to look in / busy with other stuff. Those last 3 pieces of 'news' are purely the lying Dr seeing his way through to retirement.

The guy in the glass Dr Raymond Akers Jnr, the guy in glass.

You may be like Jack Horner and "chisel" a plum,
And think you're a wonderful guy,
But the man in the glass says you're only a bum
If you can't look him straight in the eye

[norbus] 06/10/2015 08:39

That way Dr Akers can go out on a high note

They had distribution, direct sales, army contracts, and always end up the same way; Offering does not support a corporation and a greedy chairman

[rivaldo] 06/10/2015 07:17

More news - RNS re the commercialisation of two of the wellness tests:



"Akers Biosciences, Inc.

Commercializes New App-Enabled Tests for Health and Wellness Industry and Consumers

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, announces that all development specifications have been finalized and production has commenced for its two transformational breath tests designed for the health and wellness industry and consumers.

Akers Bio is launching the BreathScan OxiChek™ ("OxiChek") and BreathScan KetoChek™ ("KetoChek") tests this week at the Supply Side West conference in Las Vegas, Nevada. The conference focuses on dietary supplements and sports nutrition, two key markets for these new products.

OxiChek is the first disposable breath test to rapidly determine levels of oxidative stress (free radicals) in the body. OxiChek measures the most abundant free radicals including superoxides, hydrogen peroxide and aldehydes - unlike some pre-existing devices which measure only one. Frequent use of OxiChek may help consumers and professional clients manage and adhere to their regimen of nutritional supplementation for management of oxidative stress, which is implicated in many diseases, including cardiac, cancer and arthritic diseases.

KetoChek, and the Company's non-quantitative version, METRON®, are the only disposable breath-based diagnostic devices that rapidly determine if the subject is in the optimal fat-burning state for weight loss, known as ketosis. Achieving a state of ketosis - as indicated by the measure of breath ketones - is a goal of many individuals following low carbohydrate diets. KetoChek is a simple, non-invasive test to identify, track and quantitatively monitor breath ketones for individuals interested in maximizing weight loss.

OxiChek and KetoChek work with the new bluetooth-enabled reading device, BreathScan Lync™ and associated BreathScan™ mobile app, to enable consumers and professional users to monitor trends in critical metabolic processes via their mobile device. Clinicians, suppliers of nutritional supplements and diet plans, as well as health coaches in fitness centers, can now monitor and adjust the progress of their clients more effectively by utilizing the Company's products.

"The response to the Akers Wellness products has been overwhelmingly positive," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman. "We launched our first product, METRON®, into this market last month, including through the Amazon marketplace. Now, the Company is expanding its market reach through our efforts at Supply Side West, targeting multi-level marketing companies in the nutraceutical business, fitness and weight loss centers, chiropractors, and anti-aging medicine physicians. The Company is aggressively seeking distribution into these market segments," continued Dr. Akers.

"We believe that consumers are increasingly looking for personalized health, and that the BreathScan platform will provide the footprint for the Company to enter into the new era of digital medicine. Our new health and wellness products are poised to make an impact now as we commence production and will begin shipping this quarter. Health and wellness is a very large market segment globally and our aim is to become a significant player in this space. Whether in health and wellness or in medical diagnostics, our faster, easier diagnostic tests provide information that makes lives better," added Dr. Akers."

[algernon2] 04/10/2015 17:53

Afternoon Norbus, yes sometimes this BB seems a lonely place to be.

[norbus] 04/10/2015 11:02

mcm

come back : this is now a $billion company, and you will know how to say it. between 6 and 10 million tests a year = $billion! Wow

[algernon2] 04/10/2015 00:45

Akers Bio chief: HIT test market a billion dollar opportunity:

[norbus] 01/10/2015 15:15

They Just have to get the sales in !!!
How do you get the sales in?

[rivaldo] 01/10/2015 12:06

RNS - AKR certainly have the global distribution deals in place now, they just have to get the sales in.....



"Akers Biosciences Signs Distribution Deals in India, Germany, Italy & Scandinavia

Test for Heparin Induced Thrombocytopenia Now Represented in 30 Countries

etc"

Finncap have reiterated their 260p price target.

[algernon2] 15/9/2015 22:15

They're here.Just buy and blow!

[werewolfie] 11/9/2015 14:34

Norbus - did you notice i gave him credit for nothing else?

Craigo3 - i agree. Are we in this to make money or moan about donkey companies on these threads

[craigo3] 08/9/2015 17:00

Get out and get into a rising stock, sod these losers.

[norbus] 08/9/2015 13:38

You have given him your money, so what the hell?
you want to give him credit?
For seeking more mugs?

[algernon2] 05/9/2015 12:16

Akers Biosciences to Present at Rodman & Renshaw 17th Annual Global Investment Conference

"Executive Chairman, Raymond F. Akers Jr.,PhD.is scheduled to speak at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10, 2015.

The Rodman & Renshaw 17th Annual Global Investment Conference is being held at the St. Regis Hotel in New York with approximately 2,000 attendees."